Trial Purpose

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumour proportion score (TPS) ≥50%).

Learn More on



When speaking to your doctor, please have the trial identifier number available.

About The Study

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.

Trial start Icon


  • Actual study start date 6 February 2023
  • Estimated primary completion date 12 January 2027
  • Estimated study completion date 23 August 2028


Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon


Carcinoma, Non-Small-Cell Lung

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.